Journal_of_Drugs_in_Dermatology

<i>Journal of Drugs in Dermatology</i>

Journal of Drugs in Dermatology

Medical journal


The Journal of Drugs in Dermatology is a monthly peer-reviewed medical journal of dermatology published by Sanovaworks. The journal was established in 2002 by Mohs surgeon Perry Robins, founder of the Skin Cancer Foundation. It is the flagship publication of Sanovaworks, publisher of Derm-in-Review and Next Steps, as well as the sponsor of JDD Podcasts and two annual medical specialty conferences, Skin of Color Update (SOCU), and the ODAC Dermatology Aesthetic and Surgical (ODAC) conferences.

Quick Facts Discipline, Language ...

Editors

The following persons have been co-editor-in-chief of the journal:

  • Elizabeth Hale MD (2004)
  • Susan H. Weinkle MD (2005–2008)
  • Keyvan Nouri MD (2005–2008)
  • Sherry H. Hsiung MD (2008)
  • James M. Spencer MD (2009–2013)

Abstracting and Indexing

The journal is abstracted and indexed in the following bibliographic databases:[1]

The journal was accepted into the Science Citation Index[5] in 2003 and received an impact factor in 2004.[6] According to the Journal Citation Reports, the journal has a 2019 impact factor of 1.464.[7]


References

  1. "Journal of Drugs in Dermatology". MIAR: Information Matrix for the Analysis of Journals. University of Barcelona. Retrieved 2020-09-02.
  2. "Embase Coverage". Embase. Elsevier. Retrieved 2020-09-02.
  3. "Journal of Drugs in Dermatology y". MIAR: Information Matrix for the Analysis of Journals. University of Barcelona. Retrieved 2020-09-02.
  4. Journal of Drugs in Dermatology SanovaWorks. Retrieved 1 September 2020
  5. "Journal of Drugs in Dermatology". 2019 Journal Citation Reports. Web of Science (Science ed.). Thomson Reuters. 2019.

Share this article:

This article uses material from the Wikipedia article Journal_of_Drugs_in_Dermatology, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.